weve adjust ew sale estim cc
report vs prior cc report in-lin
incl royalti mitral/tricuspid in-lin high end guidanc
rang longer term basi modestli temper ex-u
expect tavr given higher presum payer friction price sensit
 increas explicit estim mitral/tricuspid model
ep within guidanc
thesi valuat risk invest thesi ew remain
unchang princip driven share posit tavr market
exceed link similar size mitral tricuspid
opportun circa catalyt basi believ low risk tavr
trial provid bump ww tavr market cc growth
versu part due increas surgic cannib link
ew share posit hold firm due combin effect
centera ex-u sapien ultra ww uptick market momentum
like help allay concern held regard size underli
preval pool also feel cours investor
attent becom reliabl focus mitral tricuspid adjac
patient link price target sum assign
base busi inclus tavr associ mitral
tricuspid adjac base busi dcf assum ew
tavr overal sale ex-mitral/tricuspid unburden
invest structur heart adjac presum oper
margin base busi thusli defin employ discount
rate termin growth rate presum develop non-
thvt growth driver mitral tricuspid consid termin valu
contribut combin segment assum market
ew hold share associ oper margin
point time discount rate termin growth rate
given larger patient size mitral/tricuspid adjac interven
trans-cathet learn tavr off-set increas technical/
clinic uncertainti dont feel market assumpt year
henc unreason like take tavr year achiev
sale trans-cathet mitral sale alreadi total
dont assign valu mitral/tricuspid posit cash flow prior
consider drag invest period princip risk
thesi includ over-estim address aortic mitral
tricuspid preval pool technic clinic uncertainti mitral/tricuspid
heighten competit thvt higher expect thvt price
tr target
page
page
million except per share surgeri expens inc interest incom adjust analysisgross sg analysistot sale sale cc cc ex cc incl cc incl cardioband vasc forma corpor
edward lifesci corp focus technolog treat structur heart diseas
critic ill patient design develop manufactur market product treat cardiovascular
diseas product technolog categor three area surgic heart valv therapi
transcathet heart valv critic surgic heart valv therapi portfolio includ
tissu heart valv heart valv repair product surgic replac repair patient
heart valv transcathet heart valv portfolio includ technolog design treat heart
valv diseas use catheter-bas approach oppos open surgic techniqu critic
portfolio product includ pulmonari arteri cathet dispos pressur transduc
advanc monitor system found mile lowel edward
headquart irvin ca
invest thesi ew remain unchang princip driven share posit tavr
market exceed link similar size mitral tricuspid opportun
circa catalyt basi believ low risk tavr trial provid bump
ww tavr market cc growth versu part due increas surgic
cannib link ew share posit hold firm due combin effect centera
ex-u sapien ultra ww uptick market momentum like help allay concern held
regard size underli preval pool also feel cours
investor attent becom reliabl focus mitral tricuspid adjac
preval us mitral/tricuspid patient versu aortic stenosi patient link
valuat risk
price target sum assign base busi inclus tavr
associ mitral tricuspid adjac base busi dcf assum
ew tavr overal sale ex-mitral/tricuspid unburden invest
structur heart adjac presum oper margin base busi
thusli defin employ discount rate termin growth rate presum
develop non-thvt growth driver mitral tricuspid consid termin valu
contribut combin segment assum market ew hold
share associ oper margin point time discount rate
termin growth rate given larger patient size mitral/tricuspid adjac interven
trans-cathet learn tavr off-set increas technical/clin uncertainti
dont feel market assumpt year henc unreason like take tavr
year achiev sale trans-cathet mitral sale alreadi total
dont assign valu mitral/tricuspid posit cash flow prior consider
drag invest period
princip risk thesi includ over-estim address aortic mitral tricuspid
preval pool technic clinic uncertainti mitral/tricuspid heighten competit
thvt higher expect thvt price pressur
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
